Cargando…
Interleukin‐1 Trap Rilonacept Improved Health‐Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY
BACKGROUND: Recurrent pericarditis is characterized by painful flares and inflammation, which negatively impact health‐related quality of life. RHAPSODY (rilonacept inhibition of interleukin‐1 alpha and beta for recurrent pericarditis: a pivotal symptomatology and outcomes study) evaluated the effic...
Autores principales: | Brucato, Antonio, Lim‐Watson, Michelle Z., Klein, Allan, Imazio, Massimo, Cella, David, Cremer, Paul, LeWinter, Martin M., Luis, Sushil Allen, Lin, David, Lotan, Dor, Pancrazi, Massimo, Trotta, Lucia, Klooster, Brittany, Litcher‐Kelly, Leighann, Zou, Liangxing, Magestro, Matt, Wheeler, Alistair, Paolini, John F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673658/ https://www.ncbi.nlm.nih.gov/pubmed/36250662 http://dx.doi.org/10.1161/JAHA.121.023252 |
Ejemplares similares
-
Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis
por: Brucato, Antonio, et al.
Publicado: (2023) -
Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept
por: Lin, David, et al.
Publicado: (2021) -
Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial
por: Klein, Allan L, et al.
Publicado: (2021) -
Anti-interleukin-1 agents for pericarditis: a primer for cardiologists( )
por: Imazio, Massimo, et al.
Publicado: (2021) -
Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis
por: Wang, Tom Kai Ming, et al.
Publicado: (2022)